ASX - By Stock
|
LOT |
Re:
Uranium news
|
|
Dungiven
|
81 |
35K |
3 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
81
|
35K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
Dungiven
|
465 |
140K |
8 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
465
|
140K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
Dungiven
|
465 |
140K |
21 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
465
|
140K
|
21
|
|
ASX - By Stock
|
PAR |
Re:
2x2 Yay Or Nay From The FDA?
|
|
Dungiven
|
13 |
4.2K |
12 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
13
|
4.2K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Type D Response Submitted and Received by the US FDA
|
|
Dungiven
|
46 |
15K |
6 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
46
|
15K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Type D Response Submitted and Received by the US FDA
|
|
Dungiven
|
46 |
15K |
25 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
46
|
15K
|
25
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Type D Response Submitted and Received by the US FDA
|
|
Dungiven
|
46 |
15K |
8 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
46
|
15K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Type D Response Submitted and Received by the US FDA
|
|
Dungiven
|
46 |
15K |
34 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
46
|
15K
|
34
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
Dungiven
|
465 |
140K |
12 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
465
|
140K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Dungiven
|
670 |
250K |
10 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
670
|
250K
|
10
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Appointment of Debt Advisor for Kayelekera Restart
|
|
Dungiven
|
3 |
1.1K |
4 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
3
|
1.1K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Dungiven
|
670 |
250K |
16 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
670
|
250K
|
16
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Malawian Mining Ministry Support for Kayelekera
|
|
Dungiven
|
9 |
3.2K |
1 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
9
|
3.2K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Dungiven
|
670 |
250K |
3 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
670
|
250K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Dungiven
|
670 |
250K |
10 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
670
|
250K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Dungiven
|
670 |
250K |
19 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
670
|
250K
|
19
|
|
ASX - By Stock
|
LOT |
Re:
Ann: $30million Placement for Uranium Restart & Development
|
|
Dungiven
|
31 |
13K |
3 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
31
|
13K
|
3
|
|
ASX - By Stock
|
LOT |
Re:
Ann: $30million Placement for Uranium Restart & Development
|
|
Dungiven
|
31 |
13K |
4 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
31
|
13K
|
4
|
|
ASX - By Stock
|
LOT |
Re:
Ann: $30million Placement for Uranium Restart & Development
|
|
Dungiven
|
31 |
13K |
12 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
31
|
13K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Video: Paradigm Biopharmaceuticals (ASX:PAR) conducting Phase 3 osteoarthritis trial
|
|
Dungiven
|
31 |
10K |
4 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
31
|
10K
|
4
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Trading Halt
|
|
Dungiven
|
15 |
8.1K |
4 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
15
|
8.1K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Video: Paradigm Biopharmaceuticals (ASX:PAR) conducting Phase 3 osteoarthritis trial
|
|
Dungiven
|
31 |
10K |
32 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
31
|
10K
|
32
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Trading Halt
|
|
Dungiven
|
15 |
8.1K |
17 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
15
|
8.1K
|
17
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Trading Halt
|
|
Dungiven
|
15 |
8.1K |
1 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
15
|
8.1K
|
1
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Trading Halt
|
|
Dungiven
|
15 |
8.1K |
4 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
15
|
8.1K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
Dungiven
|
327 |
101K |
9 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
327
|
101K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
Dungiven
|
327 |
101K |
8 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
327
|
101K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
Dungiven
|
327 |
101K |
20 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
327
|
101K
|
20
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
Dungiven
|
327 |
101K |
31 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
327
|
101K
|
31
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial
|
|
Dungiven
|
59 |
20K |
11 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
59
|
20K
|
11
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
Dungiven
|
327 |
101K |
2 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
327
|
101K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
Dungiven
|
327 |
101K |
31 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
327
|
101K
|
31
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
Dungiven
|
327 |
101K |
1 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
327
|
101K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
Dungiven
|
327 |
101K |
37 |
10/02/24 |
10/02/24 |
ASX - By Stock
|
327
|
101K
|
37
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Receives $7.36m R&D Tax Incentive Refund
|
|
Dungiven
|
52 |
16K |
1 |
08/02/24 |
08/02/24 |
ASX - By Stock
|
52
|
16K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Receives $7.36m R&D Tax Incentive Refund
|
|
Dungiven
|
52 |
16K |
11 |
08/02/24 |
08/02/24 |
ASX - By Stock
|
52
|
16K
|
11
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Receives $7.36m R&D Tax Incentive Refund
|
|
Dungiven
|
52 |
16K |
29 |
07/02/24 |
07/02/24 |
ASX - By Stock
|
52
|
16K
|
29
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Dungiven
|
236 |
77K |
3 |
03/02/24 |
03/02/24 |
ASX - By Stock
|
236
|
77K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Dungiven
|
236 |
77K |
17 |
03/02/24 |
03/02/24 |
ASX - By Stock
|
236
|
77K
|
17
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Dungiven
|
236 |
77K |
12 |
03/02/24 |
03/02/24 |
ASX - By Stock
|
236
|
77K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Selected for Major OA Conference Presentations
|
|
Dungiven
|
35 |
11K |
1 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
35
|
11K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Selected for Major OA Conference Presentations
|
|
Dungiven
|
35 |
11K |
16 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
35
|
11K
|
16
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Selected for Major OA Conference Presentations
|
|
Dungiven
|
35 |
11K |
48 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
35
|
11K
|
48
|
|
ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
Dungiven
|
974 |
316K |
15 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
974
|
316K
|
15
|
|
ASX - By Stock
|
LOT |
Re:
LOT Chart
|
|
Dungiven
|
224 |
95K |
1 |
25/01/24 |
25/01/24 |
ASX - By Stock
|
224
|
95K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
Dungiven
|
974 |
316K |
33 |
24/01/24 |
24/01/24 |
ASX - By Stock
|
974
|
316K
|
33
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Final planning phase for Kayelekera restart
|
|
Dungiven
|
2 |
1.5K |
9 |
16/01/24 |
16/01/24 |
ASX - By Stock
|
2
|
1.5K
|
9
|
|
ASX - By Stock
|
LOT |
Re:
Rerate
|
|
Dungiven
|
61 |
34K |
1 |
15/01/24 |
15/01/24 |
ASX - By Stock
|
61
|
34K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
Dungiven
|
974 |
316K |
32 |
11/01/24 |
11/01/24 |
ASX - By Stock
|
974
|
316K
|
32
|
|
ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
Dungiven
|
974 |
316K |
15 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
974
|
316K
|
15
|
|